Please login to the form below
Denali Therapeutics
This page shows the latest Denali Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Also working within the RIPK1 inhibitor space is Sanofi and Denali Therapeutics. ... In 2018, Sanofi paid Denali $125m upfront for access to two of the company’s RIPK1 inhibitors.
Latest news
-
Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
In August, Biogen signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for the deal. ... Denali’s portfolio of small molecule LRRK2 inhibitors and transport vehicle
-
Biogen pays Denali $1bn upfront for Parkinson’s disease programme
Deal includes portfolio of small molecule LRRK2 inhibitors. Biogen has signed an agreement with Denali Therapeutics for access to the latter’s Parkinson’s disease programme, fronting an initial $1bn for ... Denali is also eligible to receive up to
-
Takeda ties-up with Denali Therapeutics for neuroscience boost
Takeda Pharmaceuticals and Denali Therapeutics have entered a partnership to develop and commercialise therapies for multiple neurodegenerative diseases. ... At the forefront of the work will be Denali’s ATV technology, which aims to increase exposure
Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b
Biogen pays Denali $1bn upfront for Parkinson’s disease programme
Takeda ties-up with Denali Therapeutics for neuroscience boost
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
Faced with that litany of failures, researchers are branching out beyond old approaches to amyloid- beta (Abeta) in search of effective therapeutics. ... Denali Therapeutics is collaborating with Sanofi on a drug designed to alleviate inflammatory
-
Deal Watch January 2018
th. in the top deal makers of 2017, had a busy first week of the New Year, entering into an option and collaboration agreement with Denali Therapeutics paying $155m on agreement ... Acquisition company. 4, 800. Denali Therapeutics/ Takeda Pharmaceutical.
Where next in Alzheimer’s disease R&D?
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Senior Account Executive
-
Competitive Salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Manager
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Publications Director
-
Competitive Salary
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Merck & Co reveals plans for women’s health spinoff Organon
- bluebird bio aiming to separate business units by year-end
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- AbbVie lauds head-to-head win for Skyrizi versus Cosentyx
- AZ, Amgen file first-in-class asthma drug with the FDA
- Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- Clark Health promotes Siân Hurst to managing director role
- ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Merck & Co reveals plans for women’s health spinoff Organon
- Virtual agency The Difference Collective makes new hires to senior team
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- The impact of cancer on mental health during COVID-19
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
